After pledging earlier this year to bolster its drug substance capabilities in Central Europe, German chemical company Evonik is turning its attention to the U.S. The company is laying out $100 ...

Amid an ongoing expansion of China’s volume-based procurement (VBP) scheme to lower drug costs, the Chinese government has ...

After thriving on the market for more than a decade as the only treatment for Dupuytrens contracture and Peyronie’s disease, Keenova Therapeutics’ Xiaflex has excelled in a phase 3 trial that could ...

Catalent is shedding one of its U.K. manufacturing facilities as it inks a separate partnership deal to advance a new gene therapy, expanding in certain areas while scaling back in others. First up, ...

AbbVie’s Allergan Aesthetics, looking to open doors for the next generation of female leaders, welcomed a cohort of young ...

Following a major push by the industry’s heavyweights to simplify their businesses in recent years, Tanabe Pharma is | While ...

When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...

Novartis is executing more layoffs at its U.S. headquarters in East Hanover, New Jersey, handing 322 employees pink slips.

As Bristol Myers Squibb attempts to convert two accelerated oncology nods for Krazati into traditional FDA approvals, the ...

Vertex has secured a label expansion through the FDA's Commis | Vertex Pharmaceuticals has gained a label expansion from the ...

Heidi, an “AI Care Partner” that helps clinicians save time and reduce burn out through an array of AI tools, is laying out a unique set of desirable "side effects" in a new brand campaign that puts a ...

Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma (DLBLC), a positive phase 3 combination ...